Video
Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC
Author(s):
“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.
Video Player is loading.
In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Justin Dubin, MD, on the use of AI in the male infertility space
Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
Investigators compare trimodal therapy vs cystectomy in MIBC
Investigators assess ctDNA’s role in NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
Related Content
